Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 4,875 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 4,875 shares of RxSight stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $46.00, for a total transaction of $224,250.00. Following the completion of the sale, the insider now owns 42,246 shares of the company’s stock, valued at $1,943,316. This trade represents a 10.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.

RxSight Stock Performance

RXST opened at $45.12 on Wednesday. RxSight, Inc. has a one year low of $27.07 and a one year high of $66.54. The stock has a market capitalization of $1.82 billion, a P/E ratio of -54.36 and a beta of 1.19. The business’s 50-day simple moving average is $49.97 and its 200-day simple moving average is $53.04.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in RxSight by 854.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the period. Quarry LP grew its position in RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after purchasing an additional 288 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in RxSight in the third quarter valued at $34,000. Finally, Quest Partners LLC purchased a new stake in shares of RxSight in the second quarter valued at about $41,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RXST. Stifel Nicolaus decreased their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Oppenheimer cut their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Jefferies Financial Group began coverage on RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight has an average rating of “Buy” and a consensus price target of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.